← Back to Search

Monoclonal Antibodies

ANX005 for Autoimmune Hemolytic Anemia

Phase 2
Waitlist Available
Led By Morie Gertz, MD
Research Sponsored by Annexon, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to day 71
Awards & highlights

Study Summary

This trial will test a new drug, ANX005, for people with Warm Autoimmune Hemolytic Anemia. They will evaluate how safe and tolerable the drug is.

Eligible Conditions
  • Warm Autoimmune Hemolytic Anemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to day 71
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to day 71 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in disease activity biomarkers
Safety: Treatment-emergent adverse events (TEAEs)
Secondary outcome measures
Change in complement system biomarkers
Plasma concentrations

Trial Design

1Treatment groups
Experimental Treatment
Group I: ANX005Experimental Treatment1 Intervention
Participants will receive two once-weekly doses of ANX005 at specific time points
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ANX005
2020
Completed Phase 2
~50

Find a Location

Who is running the clinical trial?

Annexon, Inc.Lead Sponsor
12 Previous Clinical Trials
792 Total Patients Enrolled
Morie Gertz, MDPrincipal InvestigatorMayo Clinic, Rochester, MN
Study DirectorStudy DirectorAnnexon, Inc.
1,221 Previous Clinical Trials
499,968 Total Patients Enrolled
~2 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top